Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,37,206.82 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Ballentine Partners LLC grew its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing ...

BioLife Plasma Services LP and Takeda Pharmaceuticals USA Inc. enabled third parties to intercept the personal information of ...

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

Upbeat about China's innovative digital business environment, Takeda continues to invest in the country as it ramps up ...